UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Molecular cancer therapeutics, 2008-04, Vol.7 (4), p.759-768

2008

Volltextzugriff (PDF)

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

Clinical cancer research, 2008-06, Vol.14 (11), p.3441-3449

2008

Volltextzugriff (PDF)

Abstract LB094: KisoBody: Development and pre-clinical assessment of a novel multispecific antibody platform

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB094-LB094

2021

Volltextzugriff (PDF)

Abstract LBA018: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.LBA018-LBA018

2021

Volltextzugriff (PDF)

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Blood, 2008-08, Vol.112 (4), p.981-989

2008

Volltextzugriff (PDF)

Abstract P200: Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P200-P200

2021

Volltextzugriff (PDF)

Characterization of the Human DNA Methyltransferase Splice Variant Dnmt1b

The Journal of biological chemistry, 2000-04, Vol.275 (15), p.10754-10760

2000

Volltextzugriff (PDF)

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

British journal of haematology, 2009-11, Vol.147 (4), p.507-514

2009

Volltextzugriff (PDF)

Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity

Journal of medicinal chemistry, 2007-11, Vol.50 (23), p.5543-5546

2007

Volltextzugriff (PDF)

Abstract 324: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.324-324

2022

Volltextzugriff (PDF)

488. Development of a Robust Non-Viral Gene Delivery System for Gut Mucosal Cells

Molecular therapy, 2015-05, Vol.23, p.S194-S194

2015

Volltextzugriff (PDF)

Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1790-1790

2012

Volltextzugriff (PDF)

Identification of cis-Regulating Elements andtrans-Acting Factors Regulating the Expression of the Gene Encoding the Small Subunit of Ribonucleotide Reductase inDictyostelium discoideum

The Journal of biological chemistry, 1999-07, Vol.274 (29), p.20384-20390

1999

Volltextzugriff (PDF)

Abstract 930: Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.930-930

2013

Volltextzugriff (PDF)

Expression and characterization of a Dictyostelium discoideum annexin

Molecular and cellular biochemistry, 1994-10, Vol.139 (2), p.159-166

1994

Volltextzugriff (PDF)

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3039-3039

2012

Volltextzugriff (PDF)

Abstract 3610: Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multitargeted kinase inhibitor in clinical development, in combination with taxanes

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3610-3610

2011

Volltextzugriff (PDF)

Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A95-A95

2011

Volltextzugriff (PDF)

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors

Cancer research (Chicago, Ill.), 2002-08, Vol.62 (15), p.4325-4330

2002

Volltextzugriff (PDF)

Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3609-3609

2010

Volltextzugriff (PDF)

Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3612-3612

2010

Volltextzugriff (PDF)

Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases

Expert opinion on drug discovery, 2008-09, Vol.3 (9), p.1041-1065

2008

Volltextzugriff (PDF)

Identification of cis-regulating elements and trans-acting factors regulating the expression of the gene encoding the small subunit of ribonucleotide reductase in Dictyostelium discoideum

The Journal of biological chemistry, 1999-07, Vol.274 (29), p.20384-20390

1999

Volltextzugriff (PDF)

Biphasic expression of rnrB in Dictyostelium discoideum suggests a direct relationship between cell cycle control and cell differentiation

Differentiation (London), 2001-02, Vol.67 (1), p.12-24

2001

Volltextzugriff (PDF)

Functional analysis of capA and its product, the cAMP-binding protein CABP1, in Dictyostelium discoideum

Bonfils, Claire

1992

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Englisch
(39)
Französisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

Abstract LB094: KisoBody: Development and pre-clinical assessment of a novel multispecific antibody platform

Abstract LBA018: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Abstract P200: Pre-clinical development of a dopamine receptor 2, PD-1 and CD47 trispecific antibody for treatment of small cell lung cancer

Characterization of the Human DNA Methyltransferase Splice Variant Dnmt1b

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity

Abstract 324: Discovery of novel functional TROP2 antibodies for treatment of epithelial cancers

488. Development of a Robust Non-Viral Gene Delivery System for Gut Mucosal Cells

Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis

Identification of cis-Regulating Elements andtrans-Acting Factors Regulating the Expression of the Gene Encoding the Small Subunit of Ribonucleotide Reductase inDictyostelium discoideum

Abstract 930: Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies

Expression and characterization of a Dictyostelium discoideum annexin

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study

Abstract 3610: Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multitargeted kinase inhibitor in clinical development, in combination with taxanes

Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102)

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors

Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants

Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor

Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases

Identification of cis-regulating elements and trans-acting factors regulating the expression of the gene encoding the small subunit of ribonucleotide reductase in Dictyostelium discoideum

Biphasic expression of rnrB in Dictyostelium discoideum suggests a direct relationship between cell cycle control and cell differentiation

Functional analysis of capA and its product, the cAMP-binding protein CABP1, in Dictyostelium discoideum

Suchergebnisse filtern